Eledon Pharmaceuticals, Inc.
ELDN
$3.57
-$0.01-0.27%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -0.23% | -2.63% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.41% | 12.66% | |||
| Operating Income | 1.41% | -12.66% | |||
| Income Before Tax | -274.81% | 40.36% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -273.55% | 40.16% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -273.55% | 40.16% | |||
| EBIT | 1.41% | -12.66% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -58.09% | 51.84% | |||
| Normalized Basic EPS | -58.55% | 51.98% | |||
| EPS Diluted | -58.09% | 51.84% | |||
| Normalized Diluted EPS | -58.55% | 51.98% | |||
| Average Basic Shares Outstanding | 136.34% | 24.26% | |||
| Average Diluted Shares Outstanding | 136.34% | 24.26% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||